Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
NCT ID: NCT06671314
Last Updated: 2024-11-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
42494 participants
OBSERVATIONAL
2022-06-02
2022-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Accelerated Guideline-Directed Medical Therapy for Heart Failure
NCT07217106
A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care
NCT02807857
Heart Failure Events Reduction With Remote Monitoring and eHealth Support Investigator Initiated Trial
NCT03663907
A Study of Patients Hospitalized With Acute Heart Failure With Reduced Ejection Fraction (HFrEF)
NCT03515655
Registry BAsed Optimization Of Therapy in Heart Failure
NCT07154758
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Heart Failure Cohort
Adults hospitalized with heart failure from the Get With The Guidelines - Heart Failure (GWTG-HF) registry and enrolled in Medicare Fee-for-Service at the time of discharge. Patients had heart failure with preserved or mildly reduced ejection fraction.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Were discharged alive (any discharge disposition other than "Expired").
* Had Mildly reduced or preserved ejection fraction (41% to 60%).
* Had non-missing record of SAC/VAL use at discharge.
* Continuously enrolled in Medicare Part A \& B for the 12 months following the index HF hospitalization discharge date or until death.
Exclusion Criteria
* Patients who had dialysis as an in-hospital procedure.
* Patients with a medical history of chronic dialysis.
* Patients with an in-hospital procedure of heart transplantation.
* Patients with a medical history of heart transplantation.
* Patients with an in-hospital procedure of left ventricular assist device.
* Patients with a medical history of left ventricular assist device.
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Pharmaceuticals
East Hanover, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLCZ696DUS07
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.